| Year |
Citation |
Score |
| 2024 |
Marin A, Morales F, Walbaum B. Fibroblast growth factor receptor signaling in estrogen receptor-positive breast cancer: mechanisms and role in endocrine resistance. Frontiers in Oncology. 14: 1406951. PMID 39040443 DOI: 10.3389/fonc.2024.1406951 |
0.427 |
|
| 2024 |
Tapia-Valladares C, Valenzuela G, González E, Maureira I, Toro J, Freire M, Sepúlveda-Hermosilla G, Ampuero D, Blanco A, Gallegos I, Morales F, Erices JI, Barajas O, Ahumada M, Contreras HR, et al. Distinct Driver Pathway Enrichments and a High Prevalence of Mutations in Right Colon Cancer in Chile: A Preliminary Comparative Analysis. International Journal of Molecular Sciences. 25. PMID 38731914 DOI: 10.3390/ijms25094695 |
0.627 |
|
| 2022 |
Morales F, Pérez P, Tapia JC, Lobos-González L, Herranz JM, Guevara F, de Santiago PR, Palacios E, Andaur R, Sagredo EA, Marcelain K, Armisén R. Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells. Gene. 819: 146246. PMID 35122924 DOI: 10.1016/j.gene.2022.146246 |
0.515 |
|
| 2020 |
de Santiago PR, Blanco A, Morales F, Marcelain K, Harismendy O, Herrera MS, Armisén R. Immune-related IncRNA LINC00944 responds to variations in ADAR1 levels and it is associated with breast cancer prognosis. Life Sciences. 118956. PMID 33383047 DOI: 10.1016/j.lfs.2020.118956 |
0.647 |
|
| 2018 |
Sagredo EA, Blanco A, Sagredo AI, Pérez P, Sepúlveda-Hermosilla G, Morales F, Müller B, Verdugo R, Marcelain K, Harismendy O, Armisén R. ADAR1-mediated RNA-editing of 3'UTRs in breast cancer. Biological Research. 51: 36. PMID 30290838 DOI: 10.1186/S40659-018-0185-4 |
0.617 |
|
| Show low-probability matches. |